TITLE

Generics enter 'Golden Age,' but hurdles remain

AUTHOR(S)
Baltazar, Amanda
PUB. DATE
August 2007
SOURCE
Drug Store News;8/13/2007, Vol. 29 Issue 10, p87
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the challenges faced by generic drug manufacturers despite the growing opportunities presented to them by patent expirations of drugs manufactured by big firms in the U.S. One outcome of the opportunities for generic drug makers is a diminishing number of firms in the U.S. as they consolidate to create stronger powers and to compete generic forces coming from India. Other obstacles faced by generic makers include biogenerics, authorized generics and citizen's petitions.
ACCESSION #
26296493

 

Related Articles

  • Go Go Generics.  // Pharmaceutical Executive;Dec2009, Vol. 29 Issue 12, p24 

    The article discusses developments in the market for generic drugs since the introduction of the Hatch-Waxman Act in the U.S. in 1984. It mentions that generics comprised 70 percent of prescription drugs in the country which are promoted by health plan providers and pharmacy benefit managers...

  • Authorized generics gaining popularity. Johnsen, Michael // Drug Store News;9/26/2005, Vol. 27 Issue 12, p56 

    Reports that branded pharmaceutical companies in the U.S. are turning more and more to authorized generics as part of a viable drug life cycle. Percentage share of branded generics in the pharmaceutical market for the year ended in June 2005; Branded companies still battling generics...

  • THE HATCH-WAXMAN ACT AND MARKET EXCLUSIVITY FOR GENERIC DRUG MANUFACTURERS: AN ENTITLEMENT OR AN INCENTIVE? Mehl, Ashlee B. // Chicago-Kent Law Review;2006, Vol. 81 Issue 2, p649 

    One of Congress' central goals in enacting the Hatch-Waxman Act was to expedite and encourage earlier market entry for generic pharmaceutical products. The Act provides that a generic firm may challenge a drug patent during its term by filing paperwork with the FDA that alleges either that its...

  • Top Generic-Drug Firms Go Into Branded. DAVID SAITO-CHUNG // Investors Business Daily;10/7/2014, pB06 

    In the past, it was easy to separate the ethical-drug makers that marketed proprietary medicines and the generics makers that specialized in making copies of such branded medicines.

  • Patent-extending tactics trouble generics makers. Chater, Amanda // Drug Store News;8/28/2006, Vol. 28 Issue 10, p56 

    The article provides an overview of the performance of the generic drug industry in the United States. It describes the impact of the expirations of branded drugs' patents on the industry. Generic drug sales increased by 20.6 percent to $22.3 billion in 2005. It is estimated that $64 billion...

  • Authorized generics debate continues.  // Drug Store News;8/28/2006, Vol. 28 Issue 10, p60 

    The article reports on the controversy over the issue of authorized generic drugs in the United States. According to the article, authorized generic drugs are those that are made by a branded drug company launched to coincide with the loss of a patent of one of their own products. To manufacture...

  • Report from: Japan. Wan, Jane // Pharmaceutical Technology;May2009, Vol. 33 Issue 5, p18 

    The article focuses on the efforts of the Japanese government in implementing generic drugs and its impact to the healthcare system in Japan. It mentions that generic drug substitution was introduced to the public in April 2006 and cites the cooperation of doctors in rendering prescriptions and...

  • Generic Drugs Face Regulatory and Scientific Challenges. Wechsler, Jill // BioPharm International;Aug2013, Vol. 26 Issue 8, p10 

    The article discusses legislative, regulatory and scientific challenges facing the generic drugs sector. The developments in the sector as the U.S. Food and Drug Administration (FDA) celebrates the one-year anniversary of the Generic Drug User Fee Amendments (GDUFA) of 2012 are discussed. The...

  • Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Farfan-Portet, MarĂ­a-Isabel; Gerkens, Sophie; Lepage-Nefkens, Isabelle; Vinck, Irmgard; Hulstaert, Frank // European Journal of Health Economics;Apr2014, Vol. 15 Issue 3, p223 

    The article reflects on whether biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures. It is said that a brief reminder of the differences between generics and biosimilars is required before presenting evidence on biosimilar competition. It is also said that...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics